XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis

被引：73

作者：

Guo, Yu ^{[1
]}

Xiong, Bing-Hong ^{[2
]}

Zhang, Tao ^{[3
]}

Cheng, Yong ^{[1
]}

Ma, Li ^{[4
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China

[2] Kunming Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Hernia Surg, Sch Clin Med 1, Kunming, Peoples R China

[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400016, Peoples R China

[4] Third Hosp Mianyang, Dept Emergency, Mianyang, Peoples R China

来源：

CANCER INVESTIGATION | 2016年 / 34卷 / 02期

关键词：

Colorectal cancer; Fluorouracil; Capecitabine; Oxaliplatin; CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; ORAL CAPECITABINE; COLON-CANCER; FLUOROURACIL; LEUCOVORIN; THERAPY; 5-FLUOROURACIL/LEUCOVORIN; SURVIVAL;

D O I：

10.3109/07357907.2015.1104689

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.

引用

页码：94 / 104

页数：11

共 32 条

[1] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].

Andre, Thierry ;

Boni, Corrado ;

Navarro, Matilde ;

Tabernero, Josep ;

Hickish, Tamas ;

Topham, Clare ;

Bonetti, Andrea ;

Clingan, Philip ;

Bridgewater, John ;

Rivera, Fernando ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116

[2] Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer [J].

Arkenau, Hendrik-Tobias ;

Graeven, Ullrich ;

Kubicka, Stephan ;

Grothey, Axel ;

Englisch-Fritz, Christina ;

Kretzschmar, Albrecht ;

Greil, Richard ;

Freier, Werner ;

Seufferlein, Thomas ;

Hinke, Axel ;

Schmoll, Hans-Joachim ;

Schmiegel, Wolff ;

Porschen, Rainer .

CLINICAL COLORECTAL CANCER, 2008, 7 (01) :60-64

[3] Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials [J].

Arkenau, Hendrik-Tobias ;

Arnold, Dirk ;

Cassidy, Jim ;

Diaz-Rubio, Eduardo ;

Douillard, Jean-Yves ;

Hochster, Howard ;

Martoni, Andrea ;

Grothey, Axel ;

Hinke, Axel ;

Schmiegel, Wolff ;

Schmoll, Hans-Joachim ;

Porschen, Rainer .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5910-5917

[4] Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials [J].

Cao, Y. ;

Liao, C. ;

Tan, A. ;

Liu, L. ;

Mo, Z. ;

Gao, F. .

COLORECTAL DISEASE, 2010, 12 (01) :16-23

[5] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results [J].

Cassidy, J. ;

Clarke, S. ;

Diaz-Rubio, E. ;

Scheithauer, W. ;

Figer, A. ;

Wong, R. ;

Koski, S. ;

Rittweger, K. ;

Gilberg, F. ;

Saltz, L. .

BRITISH JOURNAL OF CANCER, 2011, 105 (01) :58-64

[6] Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J].

Cassidy, Jim ;

Clarke, Stephen ;

Diaz-Rubio, Eduardo ;

Scheithauer, Werner ;

Figer, Arie ;

Wong, Ralph ;

Koski, Sheryl ;

Lichinitser, Mikhail ;

Yang, Tsai-Shen ;

Rivera, Fernando ;

Couture, Felix ;

Sirzen, Florin ;

Saltz, Leonard .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2006-2012

[7] Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401 [J].

Comella, Pasquale ;

Massidda, Bruno ;

Filippelli, Gianfranco ;

Farris, Antonio ;

Natale, Donato ;

Barberis, Giuseppe ;

Maiorino, Luigi ;

Palmeri, Sergio ;

Cannone, Michele ;

Condemi, Giovanni .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (02) :217-226

[8] Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer [J].

Conroy, T. ;

Hebbar, M. ;

Bennouna, J. ;

Ducreux, M. ;

Ychou, M. ;

Lledo, G. ;

Adenis, A. ;

Faroux, R. ;

Rebischung, C. ;

Kockler, L. ;

Douillard, J. Y. .

BRITISH JOURNAL OF CANCER, 2010, 102 (01) :59-67

[9] Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program [J].

de Gramont, Aimery ;

Haller, Daniel G. ;

Sargent, Daniel J. ;

Tabernero, Josep ;

Matheson, Alastair ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :527-530

[10] Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:: Final report of the Spanish cooperative group for the treatment of digestive tumors trial [J].

Diaz-Rubio, Eduardo ;

Tabernero, Jose ;

Gomez-Espana, Auxiliadora ;

Massuti, Bartomeu ;

Sastre, Javier ;

Chaves, Manuel ;

Abad, Alberto ;

Carrato, Alfredo ;

Queralt, Bernardo ;

Reina, Juan Jose ;

Maurel, Joan ;

Gonzalez-Flores, Encarnacion ;

Aparicio, Jorge ;

Rivera, Fernando ;

Losa, Ferran ;

Aranda, Enrique .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4224-4230

← 1 2 3 4 →